Search

everythinglearnresearchcommunity

for

Search:↓

Anifrolumab treatment improves quality of life and reduces disease activity and steroid use in SLE patients.

CTP-543 is generally safe for treating alopecia areata.

Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.

The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.

Dutasteride may protect the brain in early Parkinson's disease.

Dutasteride potentially improves cell survival and reduces retinal damage in retinitis pigmentosa.

Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.

Deucravacitinib helped regrow hair and reduce plaques in a woman with discoid lupus erythematosus without side effects.

Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.

Dupilumab can cause psoriasis in some patients.

Dupilumab can help hair regrowth but may also trigger alopecia areata.

Dupilumab may worsen hair loss in patients with alopecia areata.

Patients with acute and subacute skin lupus respond faster to belimumab than those with chronic skin lupus.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

Dutasteride effectively treats enlarged prostate with manageable side effects.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

Completing a 14-day proxalutamide treatment significantly lowers death rates in hospitalized COVID-19 patients.

Rituximab improved her dermatomyositis better than usual treatments.

Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.

Imiquimod shows promise as a non-invasive treatment for certain HPV-related lesions, but more research is needed to optimize its use.

Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.

Upadacitinib effectively treats psoriasiform eczema and some related conditions.

RC48 shows promise for treating certain advanced cancers, but more research is needed.

Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.

Dupilumab may help hair regrowth in some patients with severe atopic dermatitis, but results vary.

Dupilumab may cause hair loss, so patients should be monitored.

Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.